Volume 20 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(9): 1598-1602
XU Jian, KONG Ling-ti. Pharmaceutical intervention based on weighted TOPSIS method on the rationality rate of apatinib prescription[J]. Chinese Journal of General Practice, 2022, 20(9): 1598-1602. doi: 10.16766/j.cnki.issn.1674-4152.002658
Citation: XU Jian, KONG Ling-ti. Pharmaceutical intervention based on weighted TOPSIS method on the rationality rate of apatinib prescription[J]. Chinese Journal of General Practice, 2022, 20(9): 1598-1602. doi: 10.16766/j.cnki.issn.1674-4152.002658
shu

Pharmaceutical intervention based on weighted TOPSIS method on the rationality rate of apatinib prescription

doi: 10.16766/j.cnki.issn.1674-4152.002658

  • Department of Pharmacy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0801

  • Received Date: 2022-04-18
    Available Online: 2022-11-29
    Abstract
  •   Objective  To establish the evaluation criteria for apatinib drug utilisation and to promote the rational use of apatinib in clinical practice through appropriate pharmaceutical interventions.  Methods  Referring to the instructions of apatinib and related clinical guidelines, the evaluation criteria for the drug utilisation of apatinib were formulated, and the weighted technique for order preference by similarity to an ideal solution (TOPSIS) was used to objectively evaluate the drug use of apatinib. Pharmaceutical intervention measures and continuous intervention were given, and finally the use of apatinib after intervention was evaluated by the weighted TOPSIS method.  Results  The baseline survey revealed that the reasonable rate of apatinib prescription was low, the relative closeness of 79 medical records was between 0.9 and 1.0, and the relative closeness of 57 medical records was between 0.6 and 0.9. The scores of dose and dose adjustment, indications and combination regimen recommended by clinical guidelines were low, with mean values of 5.00, 8.10, and 8.10 points. The researchers combined baseline investigations to formulate targeted interventions, including the utilization of hospital rational-drug-use software to formulate apatinib diagnostic-restriction rules, mobilising clinical pharmacists to go deep into clinical departments to conduct special training on apatinib rational use, and continuing to conduct apatinib special prescription reviews. The prescription rationality rate greatly improved after pharmaceutical intervention, the relative closeness of 146 medical records was between 0.9 and 1.0, and the relative closeness of 21 medical records was between 0.6 and 0.9. The scores of the "combination regimen recommended by clinical guidelines" index improved, and the mean value increased to 9.32 points.  Conclusion  The weighted TOPSIS method can objectively and comprehensively evaluate the use of apatinib, which is convenient for problem detection and timely intervention.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    MOHAMMED T J, ALBAHRI A S, ZAIDAN A A, et al. Convalescent-plasma-transfusion intelligent framework for rescuing COVID-19 patients across centralised/decentralised telemedicine hospitals based on AHP-group TOPSIS and matching component[J]. Appl Intell (Dordr), 2021, 51(5): 2956-2987. doi: 10.1007/s10489-020-02169-2
    [2]
    DING Y W, WANG J, ZHU N, et al. Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: A case report and literature review[J]. Cancer Biol Ther, 2020, 21(12): 1105-1108. doi: 10.1080/15384047.2020.1836549
    [3]
    ALBAHRI A S, HAMID R A, ALBAHRI O S, et al. Detection-based prioritisation: Framework of multi-laboratory characteristics for asymptomatic COVID-19 carriers based on integrated Entropy-TOPSIS methods[J]. Artif Intell Med, 2021, 111: 101983. DOI: 10.1016/j.artmed.2020.101983.
    [4]
    SHRESTHA N, SHAD M Y, ULVI O, et al. The impact of COVID-19 on globalization[J]. One Health, 2020, 11: 100180. doi: 10.1016/j.onehlt.2020.100180
    [5]
    DENG F M, LI Y J, LIN H R, et al. A BWM-TOPSIS hazardous waste inventory safety risk evaluation[J]. Int J Environ Res Public Health, 2020, 17(16): 5765. doi: 10.3390/ijerph17165765
    [6]
    ANSARI M T J, AL-ZAHRANI F A, PANDEY D, et al. A fuzzy TOPSIS based analysis toward selection of effective security requirements engineering approach for trustworthy healthcare software development[J]. BMC Med Inform Decis Mak, 2020, 20(1): 236. doi: 10.1186/s12911-020-01209-8
    [7]
    PARK T, MUZUMDAR J, KIM H. Digital health interventions by clinical pharmacists: A systematic review[J]. Int J Environ Res Public Health, 2022, 19(1): 532. doi: 10.3390/ijerph19010532
    [8]
    TIAN Z C, NIU X H, YAO W T. Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: A review[J]. Front Oncol, 2021, 11: 749083. doi: 10.3389/fonc.2021.749083
    [9]
    钱华, 朱雅芳, 王佳良, 等. 新型药学服务模式对患者用药安全及依从性的干预效果[J]. 中华全科医学, 2019, 17(7): 1218-1221. doi: 10.16766/j.cnki.issn.1674-4152.000905

    QIAN H, ZHU Y F, WANG J L, et al. Intervention effect of new pharmaceutical care model on drug safety and compliance of patients[J]. Chinese Journal of General Practice, 2019, 17(7): 1218-1221. doi: 10.16766/j.cnki.issn.1674-4152.000905
    [10]
    李妍, 陶宇, 陆林, 等. 低剂量阿帕替尼联合替莫唑胺治疗复发小细胞肺癌的单臂临床疗效观察[J]. 中华全科医学, 2020, 18(7): 1099-1102. doi: 10.16766/j.cnki.issn.1674-4152.001438

    LI Y, TAO Y, LU L, et al. Single arm clinical observation of low-dose apatinib combined with temozolomide in the treatment of relapsed small cell lung cancer[J]. Chinese Journal of General Practice, 2020, 18(7): 1099-1102. doi: 10.16766/j.cnki.issn.1674-4152.001438
    [11]
    付玉, 齐亮, 严丽梅. 阿帕替尼联合放化疗治疗复发伴转移宫颈癌的近期疗效及预后影响因素[J]. 中国临床研究, 2020, 33(10): 1396-1399. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK202010022.htm

    FU Y, QI L, YAN L M. Short-term efficacy and prognostic factors of apatinib combined with chemoradiotherapy in the treatment of recurrent cervical cancer with metastasis[J]. Chinese Journal of Clinical Research, 2020, 33(10): 1396-1399. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK202010022.htm
    [12]
    吴柳婷, 罗洁丽, 黄艳芳, 等. TOPSIS属性分层法在红花黄色素注射液评价的适用性评估[J]. 中国医院药学杂志, 2020, 40(8): 922-928. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202008018.htm

    WU L T, LUO J L, HUANG Y F, et al. Applicability evaluation of TOPSIS attribute stratification method in the assessment of safflower yellow injection[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(8): 922-928. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202008018.htm
    [13]
    BAFAIL O A, ABDULAAL R M. New approach for selecting a suitable recycling collection program for recovered paper and pulp recyclables using AHP-TOPSIS techniques[J]. Waste Manag Res, 2021, 39(11): 1406-1413. doi: 10.1177/0734242X21994903
    [14]
    WANG F H, SHEN L T, LI J F, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer[J]. Cancer Commun, 2019, 39(1): 10. doi: 10.1186/s40880-019-0349-9
    [15]
    PARK S, NAM C M, KIM S G, et al. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis[J]. Eur J Cancer, 2021, 144: 49-60. doi: 10.1016/j.ejca.2020.10.030
    [16]
    国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会(CSCO)肝癌专家委员会. 基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版)[J]. 中华肝脏病杂志, 2021, 29(7): 636-647.

    The Chinese Chapter of the International Hepato-Pancreato-Biliary Association; Group of Liver Surgery, Surgical Society of Chinese Medical Association, Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology. Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma (2021 version)[J]. Chinese Journal of Hepatology, 2021, 29(7): 636-647.
    [17]
    SHAO F, ZHANG H, YANG X, et al. Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review[J]. Neoplasma, 2020, 67(4): 715-723.
    [18]
    THAPA P, LEE S W H, KC B, et al. Pharmacist-led intervention on chronic pain management: A systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2021, 87(8): 3028-3042.
    [19]
    WALIANY S, SAINANI K L, PARK L S, et al. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor[J]. JACC CardioOncol, 2019, 1(1): 24-36.
    [20]
    DU Y, CAO Q, JIANG C, et al. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study[J]. Cancer Med, 2020, 9(14): 5008-5014.
    [21]
    SEMA F D, ASRES E D, WUBESHET B D. Evaluation of rational use of medicine using WHO/INRUD core drug use indicators at teda and azezo health centers, gondar town, northwest ethiopia[J]. Integr Pharm Res Pract, 2021, 10: 51-63.
    [22]
    American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S37-S47.
    [23]
    NEOGI D. Performance appraisal of select nations in mitigation of COVID-19 pandemic using entropy based TOPSIS method[J]. Cien Saude Cole, 2021, 26(4): 1419-1428.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (210) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return